Market Overview
Global Chondrosarcoma Market is expected to reach at a Significant CAGR during the forecast period 2024-2031.
Chondrosarcoma belongs to the second most common type of primary bone cancer and it primarily affects the cartilage cells of the thigh bone, arm, pelvis, and knee. The global chondrosarcoma market has witnessed significant growth in recent years due to the adoption of immune inhibitors. For instance, PD-1 and IDH inhibitors are used in the immunotherapy treatment for chondrosarcoma.
Furthermore, significant growth drivers such as increasing investments, and rising research and developments give rise to future market growth. Due to the massive rise in technological advancements in countries like the U.S. and Canada, the market is experiencing a rise in demand from North American regions. Significant key players like Pfizer Inc., Eli Lily and Company, Gatewell Oncology, and others are actively operating in the market.
Market Summary
| Metrics | Details |
| CAGR | Significant CAGR |
| Size Available for Years | 2022-2031 |
| Forecast Period | 2024-2031 |
| Data Availability | Value (US$) |
| Segments Covered | Type, Treatment, End Users |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
| Fastest Growing Region | Asia-Pacific |
| Largest Region | North America |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Others key Insights. |
For more details on this report - Request for Sample
Market Dynamics
Increasing Research and Developments for Chondrosarcoma Treatment
The global chondrosarcoma market has witnessed significant growth due to various recent research and developments. Chondrosarcoma is usually diagnosed on the basis of medical history and clinical and imaging findings. Also, advanced research and developments in treating chondrosarcoma help to accelerate market growth.
For instance, according to the National Institue of Health, an article entitled Therapeutic Targets and Emerging Treatments in Advanced Chondrosarcoma published in January 2022 states that recent studies showed several biomarkers and therapeutic targets for chondrosarcoma including IDH1/2, COL2A1, and PD-L1. In addition, several molecule-targeting agents and immunotherapy have shown favorable antitumor activities in clinical studies of patients with advanced chondrosarcoma. Thus, the above factors help to boost the market growth in the forecast period.
Rising Investments for Chondrosarcoma Treatment
Chondrosarcoma belongs to a rare type of cancer that usually develops in the bones but it can sometimes occur in the soft tissue near bones. The major investments from key companies help to drive market growth and these effective funds from national organizations and companies help to transform research discoveries into new treatments.
For instance, according to an amended registration statement, Inhibrx (INBX) has filed to raise $102 million from the sale of its common stock. The company is currently developing a range of potential treatments for rare types of cancer such as chondrosarcoma and mesothelioma, as well as other forms of cancer.
Complications Associated with Chondrosarcoma are Expected to Hamper the Market Growth
Complications generally occur when chondrosarcoma spreads to the lungs, it impacts the ability to breathe and when it spreads to the brain, it can cause altered levels of consciousness and impaired memory. Chondrosarcomas can also damage the bones and disrupt the integrity of the bone structure where the tumor is located. Thus, owing to the above factors the market is expected to hamper over the forecast period.
Market Segment Analysis
The global chondrosarcoma market is segmented based on type, treatment, end users and region.
Radiation Therapy from the Treatment Segment Accounted for Approximately 38.5% of the Global Chondrosarcoma Market Share
The rising clinical trials of chondrosarcoma globally have contributed to the growing demand for chondrosarcoma treatment. Proton radiotherapy involves the use of radiation treatment that uses a beam of protons to deliver radiation directly to the tumor. Stereotactic radiosurgery technology is the common radiation therapy that uses many small gamma rays to deliver a precise dose of radiation to the target tumor cell.
For instance, according to clinicalTrials.gov, on May 16, 2023, Quironsalud conducted a clinical trial on Hypofractionated Proton therapy in Chordomas and Chondrosarcomas of the Skull Base. The primary aim of the study is to evaluate the clinical results of radical or adjuvant treatment by proton therapy in chordomas and chondrosarcomas of the skull base using hypofractionation schemes in 5 fractions. Thus, the above factors help to accelerate the market growth.
Market Geographical Share
North America Accounted for Approximately 43.4% of the Market Share in 2022
North America has maintained a significant proportion of the chondrosarcoma market in recent years, and this trend is anticipated to continue throughout the forecast period due to the factors such as an increase in healthcare expenditures, increasing research and developments, and technological advancements in chondrosarcoma treatment.
For instance, according to the National Health Expenditure Account (NHEA), the total annual healthcare expenditure in the United States is increased by 2.7% to $4.3 trillion. Physician spending grew by an average of 3.8% per year while hospital services (4.5%) and clinical services (6.6%) had higher growth rates. Thus, the above factors help to boost the region's growth.
Market Companies
The major global players in the market include Pfizer Inc., Eli Lily and Company, Gatewell Oncology, MicroBiopharm Japan Co. Ltd., Sterling Biotech Ltd., Teva Pharmaceuticals, RPG Life Sciences, Concord Biotech Ltd., Cipla Ltd., Aspen API among others.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the chondrosarcoma market. During the height of the pandemic, many healthcare systems were overwhelmed, and non-urgent medical procedures and screenings were postponed or canceled. This led to delays in chondrosarcoma treatment research. Clinical trials are vital for developing new treatments and improving outcomes in the chondrosarcoma market.
However, the pandemic disrupted the conduct of clinical trials, with many sites temporarily halting enrollment or modifying protocols to prioritize patient safety. This has led to delays in the completion of trials and the availability of new therapies. Moreover, the focus of research and development efforts shifted during the pandemic, with a significant emphasis on developing vaccines and treatments for COVID-19. Therefore, owing to the above factors, the chondrosarcoma market is expected to be moderately affected over the forecast period.
Key Developments
- In August 2022, Inhibrx Inc. announced the European Commission has granted an orphan medicinal product designation to INBRX-109 for use as a potential therapeutic option in patients with chondrosarcoma. The drug is based on a single-domain antibody platform which comprises 2 identical camelid heavy chain-only antibody-binding domains targeting DR5.
- On March 8, 2023, researchers at the University of East Anglia developed a new drug that works against all of the main types of primary bone cancer. The breakthrough drug increases survival rates by 50 percent without the need for surgery or chemotherapy.
- In April 2020, according to MJH Life Sciences, Ivosidenib (Tibsovo) showed minimal toxicity, substantial 2-hydroxyglutarate (2-HG) reduction, and durable disease control in patients with chondrosarcoma, a rare primary malignancy of the bone, according to data from a phase I study.
Why Purchase the Report?
- To visualize the global chondrosarcoma treatment market segmentation based on the type, treatment, end users, and region, as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of global chondrosarcoma treatment market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global chondrosarcoma market report would provide approximately 69 tables, 70 figures, and 195 Pages.
Target Audience 2024
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
